Effects of compound 209 on colorectal cancer cell HT-29 in vivo and in vitro

doi:10.5246/jcps.2013.01.012

Abstract

Abstract:

Compound 209 is a newly synthesized dithiocarbamate derivative with antiproliferation activity in vitro, however, its antitumor effect in vivo and the underlying mechanisms have yet to be identified. We explored the antitumor effect of compound 209 and the possible mechanisms for its inhibition of the growth of HT-29 xenograft tumor and proliferation of HT-29 cells. Cell proliferation was evaluated with SRB assay in vitro. The results showed that compound 209 had significant antiproliferation activity on HT-29 cells. Furthermore, the xenograft HT-29 nude mouse model was used to study the antitumor effect of compound 209 in vivo. We found that compound 209 significantly inhibited tumor growth and did not cause loss of body weight or leukocytopenia. Analysis by flow cytometry indicated that compound 209 arrested HT-29 cell cycle in G₁ phase. Western blotting analysis suggested that compound 209 increased the expression of p27, cyclin E, CDK2, cyclin D1 and CDK4. These results demonstrated the antitumor effect of compound 209 and its potential use as an anticancer drug.

Key words: Dithiocarbamate, Compound 209, Cell cycle, Cell cycle-related proteins, HT-29 cell line

CLC Number:

R962

Supporting:

Xiao Jiang, Xia Yuan, Mingming Chu, Wei Guo, Jingtao Liu, Fuxiang Ran, Zemei Ge, Runtao Li^*, Jingrong Cui^*. Effects of compound 209 on colorectal cancer cell HT-29 in vivo and in vitro[J]. , DOI: 10.5246/jcps.2013.01.012.

References

[1] Len, C.; Boulognemerlot, A.S.; Postel, D.J. Agric. Food Chem. 1996, 44, 2856-2858.

[2] Hidaka, S.; Funakoshi, T.; Shimada, H.; Tsuruoka, M.; Kojima, S. J. Appl. Toxicol. 1995, 15, 267-273.

[3] Guo, B.G.; Ge, Z.M.; Cheng, T.M. Acta. Pharm. Sin. 2001, 36, 185-187.

[4] Ge, Z.M.; Li, R.T.; Cheng, T.M.; Cui, J.R. Arch. Pharm. Pharm. Med. Chem. 2001, 334, 173-176.

[5] Li, R.T.; Cheng, T.M.; Cui, J.R. P.US. Pat: 1328999, 2002.

[6] Li, R.T.; Cheng, T.M.; Cui, J.R. P.US. WO Apply No: PCT/US02/16772, 2002.

[7] Guo, W.; Ran, F.X.; Wang, R.Q.; Cui, J.R.; Li, R.T.; Cheng, T.M.; Ge, Z.M. Chin. J. Clin. Pharmacol. Ther. 2004, 9, 59-62.

[8] Zhang, N.; Guo, W.; Wang, L.; Huang, W.; Xu, B.; Ge, Z.; Li, M.; Li, R.T.; Cui, J.R. Anticancer Drugs. 2008, 19, 593-598.

[9] Jiang, X.; Kong, D.; Han, F.; Ling, X.; Liu, X.; Li, R.; Cui, J. Rapid Commun. Mass Spectrom. 2007, 21, 1599-1605.

[10] Jiang, X.; Ling, X.; Han, F.; Li, R.; Cui, J. J. Pharm. Biomed. Anal. 2007, 44, 1127-1132.

[11] Jia, L. Master. Peking University. 2010, 80-83.

[12] Tewart, Z.A.; Westfall, M.D.; Pietenpol, J.A. Trends Pharmacol. Sci. 2003, 24, 139-145.

[13] Olivier, C. Gene. 2002, 299, 35-55.

[14] Young, T.K.; Min. Z.H. Yonsei Med. J. 2005, 46, 597-613.

[15] Musgrove, E.A.; Caldon, C.E.; Barraclough, J.; Stone, A.; Sutherland, R.L. Nat. Rev. Cancer. 2011, 11, 558-572.

[16] Sherr, C.J.; Roberts, J.M. Genes Dev. 1999, 13, 1501-1512.

[17] Marco, A.V.; Zhiping, L.; Mathew, C.; Emanuele, L.; Nora, H.; Richard, G.P. Future Oncol. 2011, 7, 753-765.

[18] Chang, L.; Karin, M. Nature. 2001, 410, 37-40.

[19] Cheng, M.; Sexl, V.; Sherr, C.J.; Roussel, M.F. Proc. Natl. Acad. Sci. USA. 1998, 95, 1091-1096.

[20] Diehl, J.A.; Cheng, M.; Roussel, M.F.; Sherr, C.J. Genes Dev. 1998, 15, 3499-3511.

[21] Graff, J.R.; Konicek, B.W.; McNulty, A.M.; Wang, Z.; Houck, K.; Allen, S.; Paul, J.D.; Hbaiu, A.; Goode, R.G.; Sandusky, G.E.; Vessella, R.L.; Neubauer, B.L. J. Biol. Chem. 2000, 11, 24500-24505.